Rovin Capital UT ADV Purchases 1,029 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Rovin Capital UT ADV lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 6,426 shares of the medical equipment provider’s stock after buying an additional 1,029 shares during the period. Rovin Capital UT ADV’s holdings in Zimmer Biomet were worth $694,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Crewe Advisors LLC bought a new stake in shares of Zimmer Biomet in the 1st quarter valued at $31,000. Bangor Savings Bank acquired a new position in Zimmer Biomet in the 3rd quarter worth $31,000. Family Firm Inc. acquired a new position in Zimmer Biomet in the 2nd quarter worth $33,000. J.Safra Asset Management Corp boosted its stake in Zimmer Biomet by 712.1% in the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 235 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Zimmer Biomet in the 2nd quarter worth $43,000. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research analyst reports. UBS Group reduced their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a research note on Thursday, August 8th. JPMorgan Chase & Co. reduced their target price on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research note on Monday, September 16th. Evercore ISI reduced their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Royal Bank of Canada increased their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $124.11.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $108.18 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $21.54 billion, a P/E ratio of 20.57, a price-to-earnings-growth ratio of 2.02 and a beta of 1.02. The firm’s fifty day simple moving average is $106.37 and its two-hundred day simple moving average is $110.48. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the prior year, the business earned $1.65 earnings per share. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.